The Vincerx Pharma/Bayer CDK9 inhibitor, VIP152 (BAY 1251152) , is a once-weekly (5-30 mg) IV agent in Ph. I for cancer with >50x family-selectivity . The sulfoximine-containing molecule is derived from the oral candidate atuveciclib (interestingly with opposite sulfoximine stereochemistry) and is significantly more potent under high ATP [...]
< 1 minute read
Dec. 16, 2021
VIP152 (BAY 1251152): a DK9 Inhibitor
VIP152 (BAY 1251152)
50x family-selective CDK9 kinase inhibitor IV agent (5-30 mg QW) in Ph. I for cancer scaffold hop from atuveciclib Journal of Medicinal Chemistry Bayer, Berlin, DE / Vincerx, Palo Alto, US